No matches
Dermatology

ADVENT On Air | Best Practice for CSU - Perspectives from Allergy and Dermatology

Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria (CSU). They offer practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients.
Jason Hawkes
Nicole Chase
MD, MS
Jason Hawkes +1 more

Related resources

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

Podcast
ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis

ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis

Podcast
ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

Podcast
ADVENT On Air | Exploring PN as a Distinct and Unique Disease

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

Podcast
Barrier disruption in AD and the development of environmental and food allergies

Barrier disruption in AD and the development of environmental and food allergies

expert video
ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

Podcast
Explore the Global Burden of Pediatric AD (PEDISTAD)

Explore the Global Burden of Pediatric AD (PEDISTAD)

interactivity
Diving Below the Surface of AD: The Role of Type 2 Inflammation

Diving Below the Surface of AD: The Role of Type 2 Inflammation

expert video
The Role of Type 2 Inflammation in Moderate-to-Severe AD

The Role of Type 2 Inflammation in Moderate-to-Severe AD

expert video
Current and Emerging Therapeutic Options for Children With Atopic Dermatitis

Current and Emerging Therapeutic Options for Children With Atopic Dermatitis

expert video
Atopic Dermatitis in Children: Not Just a Skin Disease

Atopic Dermatitis in Children: Not Just a Skin Disease

expert video
Type 2 Inflammation and Its Role in Atopic Dermatitis

Type 2 Inflammation and Its Role in Atopic Dermatitis

expert video
Early Intervention and the Potential For Disease Modification in AD

Early Intervention and the Potential For Disease Modification in AD

expert video
Emerging Real-World Data on Advanced Systemic Therapies in AD

Emerging Real-World Data on Advanced Systemic Therapies in AD

expert video
Real-World Effectiveness of Advanced Systemic Treatments in AD

Real-World Effectiveness of Advanced Systemic Treatments in AD

expert video
The Importance of Early Intervention and the Potential for Disease Modification in Patients With AD

The Importance of Early Intervention and the Potential for Disease Modification in Patients With AD

expert video
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Podcast
Prurigo Nodularis: The Patient Journey

Prurigo Nodularis: The Patient Journey

interactivity
Chronic Spontaneous Urticaria Mechanism of Disease Animation

Chronic Spontaneous Urticaria Mechanism of Disease Animation

videoanimation
How the Understanding of PN has Evolved?

How the Understanding of PN has Evolved?

expert video
Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients

Expert Interview: Featuring Dr Shawn Kwatra on PN itch and impact on patients

expert video
Type 2 Inflammation Contributes to Itch and Fibrois in PN

Type 2 Inflammation Contributes to Itch and Fibrois in PN

expert video
The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
The Clinical Presentation of CSU is Heterogeneous

The Clinical Presentation of CSU is Heterogeneous

expert video
The Role of Type 2 Inflammation in Multiple Disease Trajectories

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Infographic
Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

Podcast
Latest Real-World Data on Advanced Systemic Treatments for Patients With AD

Latest Real-World Data on Advanced Systemic Treatments for Patients With AD

expert video
Potential Role of Type 2 Inflammation in the Pathogenesis of CSU

Potential Role of Type 2 Inflammation in the Pathogenesis of CSU

expert video
ADVENT On Air - Dermatology

ADVENT On Air | Expert Discussions in Dermatology

Podcast
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

expert video
KOL Video Interview – Dr. Eric Simpson

KOL Video Interview – Dr. Eric Simpson

expert video
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

slide presentation
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
KOL Video Interview – Dr Amy Paller

KOL Video Interview – Dr Amy Paller

expert video
KOL Video Interview – Dr Paula Luna

KOL Video Interview – Dr Paula Luna

expert video
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

expert video
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?

The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?

expert video
Expert Interview with Dr Jason Hawkes

Expert Interview with Dr Jason Hawkes

expert video

Learning objectives

  • Highlight the burdens of CSU, including the impact of uncontrolled disease on patients’ quality of life across multiple domains and the added challenges of comorbidities
  • Outline the diagnostic pathway and general management principles for CSU, emphasizing the need to reduce time to diagnosis and escalating treatment for patients with CSU that is uncontrolled with antihistamines
Tags
podcastdiagnosisdisease backgroundexpert insightspatient burden
MAT-GLB-2600036 - 1.0 - 01/2026

About these experts

Dermatology
MD, MS

Jason Hawkes

Dr. Hawkes is a board-certified dermatologist and Investigator at the Oregon Medical Research Center in Portland, OR and is a current Councilor in the International Psoriasis Council and serves on the NPF Medical Board and Scientific Advisory Committee

Allergy/Immunology
MD

Nicole Chase

Associate Professor of Medicine, University of Minnesota; Physician Minneapolis VA Health Care System; Partner, St. Paul Allergy & Asthma, PA

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region